DE602005024148D1 - Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma - Google Patents

Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma

Info

Publication number
DE602005024148D1
DE602005024148D1 DE602005024148T DE602005024148T DE602005024148D1 DE 602005024148 D1 DE602005024148 D1 DE 602005024148D1 DE 602005024148 T DE602005024148 T DE 602005024148T DE 602005024148 T DE602005024148 T DE 602005024148T DE 602005024148 D1 DE602005024148 D1 DE 602005024148D1
Authority
DE
Germany
Prior art keywords
temozolomide
tnfα
glioblastoma
tnf
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005024148T
Other languages
English (en)
Inventor
Ralph R Weichselbaum
Donald W Kufe
Bakhtiar Yamini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Dana Farber Cancer Institute Inc
Original Assignee
University of Chicago
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago, Dana Farber Cancer Institute Inc filed Critical University of Chicago
Publication of DE602005024148D1 publication Critical patent/DE602005024148D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0271Chimeric vertebrates, e.g. comprising exogenous cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
DE602005024148T 2004-08-25 2005-08-25 Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma Active DE602005024148D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60425104P 2004-08-25 2004-08-25
PCT/US2005/030238 WO2006026348A1 (en) 2004-08-25 2005-08-25 Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma

Publications (1)

Publication Number Publication Date
DE602005024148D1 true DE602005024148D1 (de) 2010-11-25

Family

ID=35520809

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005024148T Active DE602005024148D1 (de) 2004-08-25 2005-08-25 Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma

Country Status (7)

Country Link
US (2) US20070212298A1 (de)
EP (1) EP1781284B1 (de)
AT (1) ATE484280T1 (de)
CA (1) CA2577550C (de)
DE (1) DE602005024148D1 (de)
ES (1) ES2353606T3 (de)
WO (1) WO2006026348A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212298A1 (en) * 2004-08-25 2007-09-13 Prefix Suffix Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
US20090270397A1 (en) * 2008-04-08 2009-10-29 Orlow Seth J Methods and compositions for the treatment of cancers, such as melanomas and gliomas
WO2018177982A1 (en) 2017-03-30 2018-10-04 Administración General De La Comunidad Autónoma De Euskadi Sox1 as a prognostic and predictive biomarker in the treatment of central nervous system tumours
WO2021234178A1 (en) * 2020-05-22 2021-11-25 Philogen S.P.A TNFα IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORS
CN113058035B (zh) * 2021-03-22 2022-11-04 天津市环湖医院 替莫唑胺及其活性产物mtic的声动力新应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
EP0392300B1 (de) * 1989-04-11 1992-08-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verwendung von mindestens ein Cytokin zur Herstellung eines Arzneimittels zur systemischen Behandlung von präneoplastischen Läsionen
DE69123241T2 (de) * 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US6228356B1 (en) * 1990-12-20 2001-05-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
DE69132031T2 (de) * 1990-12-20 2000-07-13 Arch Development Corp., The University Of Chicago Kontrolle der genexpression durch ionisierende strahlung
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US7592317B1 (en) * 1994-08-11 2009-09-22 The University Of Chicago Constitutive gene expression in conjuction with ionizing radiation
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001520511A (ja) * 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション 向標的性アデノウイルス・ベクター
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6899870B1 (en) * 1998-03-11 2005-05-31 Board Of Regents, The University Of Texas System Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
US6685913B1 (en) * 1999-03-09 2004-02-03 Thomas Jefferson University Lipid soluble radioactive metal chelates for tumor therapy
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US8034791B2 (en) * 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
ES2380007T3 (es) * 2001-04-06 2012-05-07 The University Of Chicago Inducción por agentes quimioterapéuticos de la actividad del promotor Egr-1 en la terapia génica
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US6881737B2 (en) * 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US7507748B2 (en) * 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
US20070212298A1 (en) * 2004-08-25 2007-09-13 Prefix Suffix Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma

Also Published As

Publication number Publication date
ES2353606T3 (es) 2011-03-03
US20070212298A1 (en) 2007-09-13
EP1781284A1 (de) 2007-05-09
WO2006026348A1 (en) 2006-03-09
EP1781284B1 (de) 2010-10-13
CA2577550C (en) 2012-10-16
US20110091375A1 (en) 2011-04-21
CA2577550A1 (en) 2006-03-09
ATE484280T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
EA200971053A1 (ru) Способы лечения кожных язв
ATE302003T1 (de) Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion
DK2195013T3 (da) Terapeutisk anvendelse af en vækstfaktor, METRNL
DE602005008241D1 (de) Zusammensetzung mit einem survivin-antisense-oligonucleotid und gemcitabin zur behandlung von krebs
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
ATE500832T1 (de) Kombination von zd6474 und pemetrexed
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
NO20082566L (no) Kombinasjon av AZ2171 og permetrexed
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
ATE447974T1 (de) Kombinationstherapie mit azd2171 und 5-fu und/oder cpt-11
NO20064754L (no) Kombinasjonsterapi
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE338560T1 (de) Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.